Silicon Investor
SI
SI

 Biotech / Medical : Elan Corporation, plc (ELN)

 Public Reply | Prvt Reply | Mark as Last Read | FilePrevious 10 | Next 10 | Previous | Next  
To: Robohogs who wrote (6097)11/24/2004 2:49:18 AM
From: AJ BergerRead Replies (2) of 10345
 
"This was the very best outcome that could have happened"

actually, the only sad part of the story is how Avonex did not seem to add to Tysabri's effectiveness. BIIB shareholders are not going to enjoy this windfall as much as ELN shareholders will, and more importantly, and as good as 66% is, I'm sure most MS sufferers were hoping that Tysabri would ADD 66% to the benefit they already felt, not replace it. At least MS sufferers with little benefit from Avonex, or adverse reactions to it, now have some solid alternative to the other 4 drugs they may not be able to use either.
Report TOU ViolationShare This Post
 Public Reply | Prvt Reply | Mark as Last Read | FilePrevious 10 | Next 10 | Previous | Next  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
Copyright © 1995-2013 Knight Sac Media. All rights reserved.